Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS7 | Q9UKP4 | 2/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 7/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.43 |
| ▸ | MMP9 | P14780 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 4/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | BMP1 | P13497 | 6/20 | 0.39 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265260 | 1.00 | ADAMTS7 (0.47) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1800637 | 0.93 | ADAMTS7 (0.48) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1800636 | 0.93 | ADAMTS7 (0.48) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1800053 | 0.81 | ADAMTS7 (0.48) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1800054 | 0.81 | ADAMTS7 (0.48) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1798488 | 0.80 | ADAMTS7 (0.54) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1798485 | 0.80 | ADAMTS7 (0.54) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1799220 | 0.79 | ADAMTS7 (0.45) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL1799218 | 0.79 | ADAMTS7 (0.45) | ADAMTS7ADAMTS5MMP13MMP2MMP9 | |
| SCHEMBL4290245 | 0.78 | MMP13 (0.44) | MMP13MMP2MMP9MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | claimed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | claimed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | ADAMTS7 21/4885ADAMTS5 19/4885MMP13 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.